62 results
8-K
EX-99.1
IOBT
IO Biotech Inc
14 May 24
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
8:30am
for accelerated approval in the US.
The independent data monitoring committee (IDMC) for the company’s IOB-013/KN-D18 Phase 3 trial convened its fourth
DEFA14A
IOBT
IO Biotech Inc
24 Apr 24
Additional proxy soliciting materials
4:06pm
as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. NOTE: The transaction of such other business
S-8
EX-23.1
IOBT
IO Biotech Inc
11 Mar 24
Registration of securities for employees
4:56pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement
S-8
EX-5.1
eg5xb875 40rx
11 Mar 24
Registration of securities for employees
4:56pm
S-8
zzsnncl8sz31jran91mb
11 Mar 24
Registration of securities for employees
4:56pm
8-K
EX-99.1
0ff 6a2coa
5 Mar 24
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
4:46pm
8-K
EX-99.1
dq72sk56dalm8 khf
8 Jan 24
Regulation FD Disclosure
8:11am
424B2
8me9yudnu80r4l
12 Sep 23
Prospectus for primary offering
4:06pm
8-K
EX-99.2
kjey 2eg1e6j71ji54xk
7 Aug 23
IO Biotech, Inc. Announces $75 Million Private Placement Financing
8:31am